Zoetis (NYSE:ZTS) Reaches New 52-Week Low – Should You Sell?

by · The Cerbat Gem

Zoetis Inc. (NYSE:ZTS – Get Free Report)’s stock price reached a new 52-week low on Monday . The stock traded as low as $70.54 and last traded at $70.6070, with a volume of 434683 shares. The stock had previously closed at $71.40.

Wall Street Analyst Weigh In

Several analysts have issued reports on ZTS shares. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Zoetis in a research report on Wednesday, September 9th. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research note on Tuesday, August 25th. Barclays cut their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Finally, Stifel Nicolaus cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $101.08.

View Our Latest Report on Zoetis

Zoetis Price Performance

The firm has a market cap of $29.39 billion, a P/E ratio of 11.70, a PEG ratio of 1.67 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company’s 50-day moving average is $75.31 and its two-hundred day moving average is $89.74.

Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Institutional Trading of Zoetis

Several large investors have recently bought and sold shares of the business. University of Texas Texas AM Investment Management Co. bought a new stake in Zoetis in the second quarter worth approximately $25,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $28,000. Root Financial Partners LLC increased its stake in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. Finally, Wellington Grp LLC increased its stake in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

(Get Free Report)

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

See Also